Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.44 CHF | -0.94% | +5.06% | -2.65% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Mar. 27 | Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.65% | 96.31M | |
+12.05% | 9.18B | |
-16.14% | 4.78B | |
+4.07% | 3.87B | |
+19.02% | 3.73B | |
+25.32% | 2.52B | |
-27.48% | 2.27B | |
-25.70% | 2.21B | |
+7.46% | 1.95B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SANN Stock
- News Santhera Pharmaceuticals Holding AG
- Santhera Pharmaceuticals Secures Future Financing With Issuance Of Treasury Shares